Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Heuson, 1976, Current overview of EORTC clinical trials with tamoxifen, Cancer Treat Rep, 60, 1463

Mouridsen, 1978, Tamoxifen in advanced breast cancer, Cancer Treat Rev, 5, 131, 10.1016/S0305-7372(78)80017-6

Legha, 1979, Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy, JAMA, 242, 49, 10.1001/jama.1979.03300010033023

Margreiter, 1984, Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer, Breast Cancer Res Treat, 4, 45, 10.1007/BF01806987

Jackson, 1991, Tamoxifen and other antiestrogens, In: Powles TJ, Smith IE, editors. Medical management of breast cancer, 51

1983, Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation, Lancet, 1, 257

1985, Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation, Lancet, 1, 836

Fisher, 1986, Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial, J Clin Oncol, 4, 459, 10.1200/JCO.1986.4.4.459

Adjuvant, 1987, Edinburgh, Lancet, 2, 171

Fisher, 1989, A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptorpositive tumors, N Engl J Med, 320, 479, 10.1056/NEJM198902233200802

1988, CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer, Br J Cancer, 57, 604, 10.1038/bjc.1988.137

Rutqvist, 1991, Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy, J Natl Cancer Inst, 83, 1299, 10.1093/jnci/83.18.1299

Fisher, 1991, New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent [editorial], J Natl Cancer Inst, 83, 1278, 10.1093/jnci/83.18.1278

Powles, 1989, A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer, Br J Cancer, 60, 126, 10.1038/bjc.1989.235

Furr, 1979, Tamoxifen (review), In: Goldberg ME, editor. Pharmacological and biochemical properties of drug substances. Vol 2., 355

Adam, 1981, Pharmacokinetic studies with Nolvadex, Reviews on Endocrine- Related Cancer, (9 Suppl), 131

Wakeling, 1984, Non-steroidal antioestrogens— receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells, J Steroid Biochem, 20, 111, 10.1016/0022-4731(84)90197-3

Jordan, 1987, Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III, Cancer Res, 47, 4517

Terenius, 1971, Effect of anti-oestrogens on initiation of mammary cancer in the female rat, Eur J Cancer, 7, 65, 10.1016/0014-2964(71)90096-X

Jordan, 1976, (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata, Eur J Cancer, 12, 419, 10.1016/0014-2964(76)90030-X

Jordan, 1980, Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model, Eur J Cancer, 16, 239, 10.1016/0014-2964(80)90156-5

Rossner, 1984, Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen, Atherosclerosis, 52, 339, 10.1016/0021-9150(84)90064-9

Bertelli, 1988, Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels, Breast Cancer Res Treat, 12, 307, 10.1007/BF01811244

Bruning, 1988, Tamoxifen, serum lipoproteins and cardiovascular risk, Br J Cancer, 58, 497, 10.1038/bjc.1988.248

Love, 1990, Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer, J Natl Cancer Inst, 82, 1327, 10.1093/jnci/82.16.1327

Bagdade, 1990, Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition, J Clin Endocrinol Metab, 70, 1132, 10.1210/jcem-70-4-1132

Furr, 1984, The pharmacology and clinical uses of tamoxifen, Pharmacol Ther, 25, 127, 10.1016/0163-7258(84)90043-3

Love, 1992, Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer, N Engl J Med, 326, 852, 10.1056/NEJM199203263261302

Fisher, 1997, Highlights of the NSABP breast cancer prevention trial, Cancer Control, 4, 78, 10.1177/107327489700400111

Gail, 1989, Projecting individualized probabilities of developing breast cancer for white females who are being examined annually, J Natl Cancer Inst, 81, 1879, 10.1093/jnci/81.24.1879

Efron, 1971, Forcing a sequential experiment to be balanced, Biometrika, 58, 403, 10.1093/biomet/58.3.403

Fleming, 1984, Designs for group sequential tests, Controlled Clin Trials, 5, 348, 10.1016/S0197-2456(84)80014-8

Freedman, 1996, Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative, Controlled Clin Trials, 17, 509, 10.1016/S0197-2456(96)00016-5

Rosner, 1995, Fundamentals of biostatistics. 4th ed., 590

Korn, 1992, Applications of crude incidence curves, Stat Med, 11, 813, 10.1002/sim.4780110611

Radloff, 1977, The CES-D scale: a self-report depression scale for research in the general public, Appl Psychol Meas, 1, 385, 10.1177/014662167700100306

Stewart, 1992, Measuring functioning and well-being: the Medical Outcomes Study approach, 10.7249/CB361

Sporn, 1984, Role of retinoids in differentiation and carcinogenesis, J Natl Cancer Inst, 73, 1381

Szarka, 1994, Chemoprevention of cancer, Curr Probl Cancer, 18, 6, 10.1016/0147-0272(94)90003-5

Bernstein, 1992, Prospects for the primary prevention of breast cancer, Am J Epidemiology, 135, 142, 10.1093/oxfordjournals.aje.a116267

Lippman, 1993, Chemoprevention, Strategies for the control of cancer. Cancer, 72(3 Suppl), 984

Prentice, 1988, Aspects of the rationale for the Women's Health Trial, J Natl Cancer Inst, 80, 802, 10.1093/jnci/80.11.802

Veronesi, 1992, Chemoprevention of breast cancer with retinoids, J Natl Cancer Inst Monogr, 12, 93

Bur, 1992, Estrogen receptor immunohistochemistry in carcinoma in situ of the breast, Cancer, 69, 1174, 10.1002/cncr.2820690518

Poller, 1993, Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein, Br J Cancer, 68, 156, 10.1038/bjc.1993.305

Giri, 1989, Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: an immunohistological study, Histopathology, 15, 575, 10.1111/j.1365-2559.1989.tb01623.x

Barnes, 1990, Potential value of hormone receptor assay in carcinoma in situ of breast, Am J Clin Pathol, 94, 533, 10.1093/ajcp/94.5.533

Rutqvist, 1993, Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen, The Stockholm Breast Cancer Study Group. J Natl Cancer Inst, 85, 1398, 10.1093/jnci/85.17.1398

McDonald, 1995, Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial, The Scottish Cancer Trials Breast Group. BMJ, 311, 977

Costantino, 1997, Coronary heart disease mortality and adjuvant tamoxifen therapy, J Natl Cancer Inst, 89, 776, 10.1093/jnci/89.11.776

Melton, 1990, Screening for osteoporosis, Ann Intern Med, 112, 516, 10.7326/0003-4819-112-7-516

Fisher, 1996, Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors, J Natl Cancer Inst, 88, 1529, 10.1093/jnci/88.21.1529

Stearns, 1998, Does tamoxifen cause cancer in humans?, J Clin Oncol, 16, 779, 10.1200/JCO.1998.16.2.779

1996, ACOG committee on Gynecologic Practice. Committee opinion, 1

Assikis, 1996, A realistic clinical perspective of tamoxifen and endometrial carcinogenesis, Eur J Cancer, 32A, 1464, 10.1016/0959-8049(96)00184-0

Katase, 1998, The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma, Cancer, 82, 1698, 10.1002/(SICI)1097-0142(19980501)82:9<1698::AID-CNCR16>3.0.CO;2-#

Ragaz, 1898, Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes, J Clin Oncol, 16, 2018, 10.1200/JCO.1998.16.6.2018

Magriples, 1993, High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients, J Clin Oncol, 11, 485, 10.1200/JCO.1993.11.3.485

Fisher, 1996, A commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients, J Clin Oncol, 14, 1027, 10.1200/JCO.1996.14.3.1027

Fisher, 1994, Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14, J Natl Cancer Inst, 86, 527, 10.1093/jnci/86.7.527

Gorin, 1998, Long-term tamoxifen citrate use and potential ocular toxicity, Am J Ophthalmol, 125, 493, 10.1016/S0002-9394(99)80190-1

Fisher, 1992, Systemic therapy in node-negative patients: updated findings from NSABP clinical trials, National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr, 11, 105

Saphner, 1991, Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer, J Clin Oncol, 9, 286, 10.1200/JCO.1991.9.2.286

1988, Nolvadex' Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer, Br J Cancer, 57, 608, 10.1038/bjc.1988.138

Cummings, 1998, Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial [abstract], Proc Am Soc Clin Oncol, 17, 2a

Veronesi, 1998, Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women, Italian Tamoxifen Prevention Study. Lancet, 352, 93

Powles, 1998, Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, Lancet, 352, 98, 10.1016/S0140-6736(98)85012-5

1997, International classification of diseases. 9th rev, Clinical modification. 5th ed., 115